Supernus Pharmaceuticals (SUPN) PT Raised to $47 at Piper Sandler
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts SUPN Hot Sheet
Price: $27.99 -0.57%
Rating Summary:
9 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Rating Summary:
9 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Join SI Premium – FREE
Piper Sandler analyst David Amsellem raised the price target on Supernus Pharmaceuticals (NASDAQ: SUPN) to $47.00 (from $40.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Piper Sandler Resumes Supernus Pharmaceuticals (SUPN) at Overweight
- Sprout Social Inc. (SPT) PT Raised to $15 at Stifel
- United Therapeutics Corp. (UTHR) PT Raised to $720 at Raymond James
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
